Alto Neuroscience, Inc. Increase (Decrease) in Accounts Payable
Alto Neuroscience, Inc. (ANRO) reported Increase (Decrease) in Accounts Payable of $2.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-12
- Alto Neuroscience, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $652.00K, a 101.86% increase year-over-year.
- Alto Neuroscience, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.49M.
- Alto Neuroscience, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$297.00K.
- Alto Neuroscience, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $461.00K, a 12.71% increase year-over-year.
- Alto Neuroscience, Inc. increase (decrease) in accounts payable for fiscal 2025 was $221.00K, a 57.17% decline from fiscal 2024.
- Alto Neuroscience, Inc. increase (decrease) in accounts payable for fiscal 2024 was $516.00K.
- Alto Neuroscience, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$632.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $652.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.14M 10-Q · filed 2026-08-12 | $1.84M derived: sum of 3 quarters · filed 2026-08-12 | $2.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.49M 10-Q · filed 2026-05-13 | $1.19M derived: sum of 2 quarters · filed 2026-05-13 | $1.65M derived: sum of 3 quarters · filed 2026-05-13 | $1.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $164.00K derived: sum of 2 quarters · filed 2026-03-16 | $487.00K derived: sum of 3 quarters · filed 2026-08-12 | $221.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $461.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $784.00K derived: sum of 2 quarters · filed 2026-08-12 | $518.00K 10-Q · filed 2025-11-12 | -$244.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $323.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $57.00K 10-Q · filed 2026-08-12 | -$705.00K derived: sum of 3 quarters · filed 2026-08-12 | -$296.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$266.00K 10-Q · filed 2026-05-13 | -$1.03M derived: sum of 2 quarters · filed 2026-05-13 | -$619.00K derived: sum of 3 quarters · filed 2026-05-13 | -$870.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$762.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$353.00K derived: sum of 2 quarters · filed 2026-03-16 | -$604.00K derived: sum of 3 quarters · filed 2026-03-16 | $516.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $409.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $158.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.28M 10-Q · filed 2025-11-12 | $497.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $869.00K 10-Q · filed 2025-08-13 | $88.00K derived: sum of 3 quarters · filed 2025-08-13 | -$553.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.12M 10-Q · filed 2025-05-14 | $339.00K derived: sum of 2 quarters · filed 2025-05-14 | -$302.00K derived: sum of 3 quarters · filed 2025-05-14 | $1.14M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$781.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$1.42M derived: sum of 2 quarters · filed 2025-03-20 | $17.00K derived: sum of 3 quarters · filed 2025-03-20 | -$632.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$641.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $798.00K derived: sum of 2 quarters · filed 2024-11-12 | $149.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $790.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$649.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |